Abstract
Cognitive behavioral therapy (CBT) has been shown to be an effective intervention for anxiety disorders. However, despite its proven efficacy, some patients fail to respond to an adequate course of treatment. In attempts to improve the efficacy of CBT, researchers have augmented the core learning processes of the intervention with d-cycloserine (DCS), an N-Methyl-D-Aspartate partial agonist. This article reviews the current literature on DCS as an augmentation strategy for CBT for anxiety disorders. We will describe the memory enhancing properties of DCS, review findings from randomized controlled studies of DCS in anxious populations and discuss mechanism, dosing and timing issues.
Keywords: D-cycloserine, anxiety, cognitive behavioral therapy
Current Pharmaceutical Design
Title:D-Cycloserine as an Augmentation Strategy for Cognitive Behavioral Therapy for Anxiety Disorders: An Update
Volume: 18 Issue: 35
Author(s): Stefan G. Hofmann, Alice T. Sawyer and Anu Asnaani
Affiliation:
Keywords: D-cycloserine, anxiety, cognitive behavioral therapy
Abstract: Cognitive behavioral therapy (CBT) has been shown to be an effective intervention for anxiety disorders. However, despite its proven efficacy, some patients fail to respond to an adequate course of treatment. In attempts to improve the efficacy of CBT, researchers have augmented the core learning processes of the intervention with d-cycloserine (DCS), an N-Methyl-D-Aspartate partial agonist. This article reviews the current literature on DCS as an augmentation strategy for CBT for anxiety disorders. We will describe the memory enhancing properties of DCS, review findings from randomized controlled studies of DCS in anxious populations and discuss mechanism, dosing and timing issues.
Export Options
About this article
Cite this article as:
G. Hofmann Stefan, T. Sawyer Alice and Asnaani Anu, D-Cycloserine as an Augmentation Strategy for Cognitive Behavioral Therapy for Anxiety Disorders: An Update, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530916
DOI https://dx.doi.org/10.2174/138161212803530916 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Novel Therapeutic Agents for Hyperuricemia in Patients with Gout
Current Drug Therapy Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on the Pharmacological Treatment of Pathological Gambling
Current Psychopharmacology Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Current Pharmaceutical Analysis The Antiprogestogen Mifepristone: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules
Current Pharmaceutical Design Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Hepatoprotective Effects and Antioxidant Potential of Polyherbal Formulation Against CCl4- Induced Hepatic Injury in Albino Rats
Current Traditional Medicine Novel Therapies for Cytomegalovirus Disease
Recent Patents on Anti-Infective Drug Discovery The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets